125 related articles for article (PubMed ID: 16626165)
1. Immunostimulants revisited: focus on the pharmacology of Ribomunyl.
Portalès P; Clot J
BioDrugs; 2006; 20(2):81-4. PubMed ID: 16626165
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of ribosomal immunotherapy.
Clot J
Drugs; 1997; 54 Suppl 1():33-6. PubMed ID: 9378077
[TBL] [Abstract][Full Text] [Related]
3. Role of ribomunyl((r)) in the prevention of recurrent respiratory tract infections in adults : overview of clinical results.
Bousquet J; Oliveri D
Treat Respir Med; 2006; 5(5):317-24. PubMed ID: 16928145
[TBL] [Abstract][Full Text] [Related]
4. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist.
Herberhold S; Coch C; Zillinger T; Hommertgen B; Busch N; Schuberth C; Hartmann E; Wimmenauer V; Hagmann CA; Lüdenbach B; Schlee M; Bootz F; Hartmann G; Barchet W
Antivir Ther; 2011; 16(5):751-8. PubMed ID: 21817197
[TBL] [Abstract][Full Text] [Related]
5. Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review.
Bousquet J; Fiocchi A
Paediatr Drugs; 2006; 8(4):235-43. PubMed ID: 16898854
[TBL] [Abstract][Full Text] [Related]
6. The immunostimulant RU41740 from Klebsiella pneumoniae activates human cells in whole blood to potentially stimulate innate and adaptive immune responses.
Pedraza-Sánchez S; González-Hernández Y; Escobar-Gutiérrez A; Ramachandra L
Int Immunopharmacol; 2006 Apr; 6(4):635-46. PubMed ID: 16504927
[TBL] [Abstract][Full Text] [Related]
7. [Cell-mediated immunity using anti-influenza vaccine (AIV) and an immunostimulant (R)].
Sabbah A; Bonneau JC; Le Dauphin C; Heulin MG
Allerg Immunol (Paris); 1988 Dec; 22 Suppl 10():40-8. PubMed ID: 3245885
[TBL] [Abstract][Full Text] [Related]
8. Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections.
Nikolova M; Stankulova D; Taskov H; Nenkov P; Maximov V; Petrunov B
Int Immunopharmacol; 2009 Apr; 9(4):425-32. PubMed ID: 19186221
[TBL] [Abstract][Full Text] [Related]
9. From Peyer's patches to tonsils. Specific stimulation with ribosomal immunotherapy.
Béné MC; Faure GC
Drugs; 1997; 54 Suppl 1():24-8. PubMed ID: 9378075
[TBL] [Abstract][Full Text] [Related]
10. [The correction of the immune system by using the immunomodulator ribomunyl in patients with recurrent respiratory tract infections].
Gordienko SM; Lasitsa OI; Misharina ZhA; Fedorchuk AG
Ter Arkh; 1995; 67(6):32-8. PubMed ID: 7667777
[TBL] [Abstract][Full Text] [Related]
11. Identification of a clinical-grade maturation factor for dendritic cells.
Boccaccio C; Jacod S; Kaiser A; Boyer A; Abastado JP; Nardin A
J Immunother; 2002; 25(1):88-96. PubMed ID: 11924914
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant.
Kolopp-Sarda MN; Béné ME; Allaire JM; Perruchet AM; Faure GC
Int J Immunopharmacol; 1997 Mar; 19(3):181-6. PubMed ID: 9306157
[TBL] [Abstract][Full Text] [Related]
13. Fish cell cultures as in vitro models of inflammatory responses elicited by immunostimulants. Expression of regulatory genes of the innate immune response.
Fierro-Castro C; Barrioluengo L; López-Fierro P; Razquin BE; Villena AJ
Fish Shellfish Immunol; 2013 Sep; 35(3):979-87. PubMed ID: 23872473
[TBL] [Abstract][Full Text] [Related]
14. Primary leukocyte screens for innate immune agonists.
Goodchild A; Nopper N; Craddock A; Law T; King A; Fanning G; Rivory L; Passioura T
J Biomol Screen; 2009 Jul; 14(6):723-30. PubMed ID: 19525489
[TBL] [Abstract][Full Text] [Related]
15. Immune response modifiers--mode of action.
Schiller M; Metze D; Luger TA; Grabbe S; Gunzer M
Exp Dermatol; 2006 May; 15(5):331-41. PubMed ID: 16630072
[TBL] [Abstract][Full Text] [Related]
16. Bacterial lysates in the prevention of respiratory tract infections.
Jurkiewicz D; Zielnik-Jurkiewicz B
Otolaryngol Pol; 2018 Oct; 72(5):1-8. PubMed ID: 30460909
[TBL] [Abstract][Full Text] [Related]
17. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
19. Innate and adaptive immune pathways to tolerance.
Thornton CA; Morgan G
Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():45-57; discussion 57-61, 251-7. PubMed ID: 19710514
[TBL] [Abstract][Full Text] [Related]
20. [The role of various forms of ribomunyl in recurrent respiratory tract infections].
Girard JP; Gumowski PI; Chavaz A; Lech B
Schweiz Med Wochenschr; 1988 Jun; 118(22):856-61. PubMed ID: 3291110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
